Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "Increased Ocular Pressure" patented technology

Use Of A Viscoelastic Composition For Treating Increased Intraocular Pressure

A viscoelastic medium is useful for the manufacture of a medicament, such as a medical device, for treatment of increased intraocular pressure in the eye of a human or animal. The medicament is administerable into at least one sclerally penetrating fistula of the eye such that the fistula is filled with the medicament. The medium is also useful in a method of treating increased intraocular pressure in the eye of a human or an animal in need thereof, comprising the step of injecting the viscoelastic medium into at least one sclerally penetrating fistula in the eye such that the fistula is filled with the medium.
Owner:Q MED AB

Method for laser treatment for glaucoma

ActiveUS10744034B2Reduce convexityEnlarging the drainage angleUltrasound therapyLaser surgeryOcular tensionDrainage angle
Because vision loss in most forms of glaucoma is related to elevated IOP, most glaucoma treatment protocols are concerned with lowering IOP by increasing aqueous humor outflow. The invention utilizes electromagnetic radiation to create retraction in the iris tissue, thereby (a) reducing convexity and enlarging the drainage angle and thus the area of the anterior chamber, (b) reducing contact between the zonule fibers and the iris pigment epithelium, (c) applying greater tension to both the TM and uveoscleral outflow pathways, thereby enlarging those pathways and increasing outflow.
Owner:HOMER GREGG S

Device for treating ocular diseases caused by increased intraocular pressure

InactiveUS20160302967A1Increased intraocular pressureDecreasing tube exposure dangerEye surgeryWound drainsDonated tissueBaerveldt Implants
One or more example embodiments relate to a device for treating ocular diseases caused by an increased intraocular pressure. The device for treating ocular diseases according to one or more example embodiments, compared to a conventional Ahmed valve implant and Baerveldt implant, does not require a donated tissue, reduces tube exposure danger, allows intraocular pressure to be easily controlled after surgery, has a slight effusion of aqueous humor to the surrounding due to a small perforated window, decreases the types and number of postoperative interventions, and decreases the number of patients with early postoperative complications.
Owner:SAMSUNG LIFE PUBLIC WELFARE FOUND

Methods for treating glaucoma and macular degeneration

Inhibition of geranylgeranylation of Rho GTPases and heterotrimeric G-proteins in the aqueous outflow pathway increases aqueous humor outflow, possibly through the tissue relaxation, and through altered cell adhesive interactions and actin cytoskeletal organization in cells of the outflow pathway. In addition, such inhibition is useful for treating age-related macular degeneration. The GGTase-I enzyme is a molecular target for lowering increased ocular pressure in glaucoma patients.
Owner:PHARMACO INVESTMENTS

Method and apparatus for reducing intraocular pressure

A drainage apparatus is disclosed to reduce intraocular pressure in an eyeball that includes an anterior chamber having aqueous humor disposed therein, a cornea and a surrounding marginal limbus by which the cornea is continuous with a scleral layer and a conjunctival layer disposed on an exposed surface of the eyeball and under eyelids, the apparatus comprising an inlet assembly configured to be disposed at the anterior chamber of the eyeball, an outlet assembly configured to be disposed at the external surface of the eyeball, the assembly having a central chamber, a tube extending between the inlet and outlet assemblies and configured to promote fluid communication between the inlet and outlet assemblies, and control means disposed within the outlet assembly for controlling a flow of aqueous humor through the tube from the anterior chamber of the eyeball to the external surface of the eyeball, the control means further comprising a replaceable filter disposed within the central chamber of the outer member to prevent intraocular infection, the filter having a medicinal agent applied thereto for preventing occlusion of the filter or bacterial contamination by inhibiting at least one of the formation of fibrotic membranes, inflammatory membrane, or bacterial adhesions or biofilms, thereby preventing increased of intraocular pressure or infection.
Owner:CAMRAS VISION

EP4 Receptor Agonist, Compositions and Methods Thereof

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
Owner:MERCK & CO INC

Multifunctional bed for post-vitrectomy rehabilitation

The invention discloses a multifunctional bed for post-vitrectomy rehabilitation. The multifunctional bed comprises bed frame and a bed body, wherein the bed body is horizontally arranged on the bed frame, is used for supporting a human body and is formed by sequentially arranging a height-adjustable headrest supporting part, a fixed body supporting part and dip-angle-adjustable lower limb supporting part from a bedside end to a bed tail end, and a pair of front face clamping-supporting parts are formed in the middle of the headrest supporting part at intervals along the length direction of the bed frame. The multifunctional bed has the advantages that the structure is simple, the operation is simple and convenient, and different forced postures can be easily switched. The easy switching between two postures, namely a prostrate posture and a sitting posture of a post-vitrectomy patient is realized, so that the smooth breathing of the patient is guaranteed, untoward effects of dizziness, chest distress, neck muscle fatigue and ache, limb numbness, face edema, skin pressure sores, increase of intraocular pressure and the like caused to long-term maintenance of the patient are avoided, and the comfort level of the patient is increased; and the patient can maintain a face-down forced posture for a long time, thereby benefiting postoperative rehabilitation.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Novel maxi-k channel blockers, methods of use and process for making the same

InactiveUS20050239863A1Elevated intraocular pressureBiocideSenses disorderIntra ocular pressureElevated intraocular pressure
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of a mammalian species, particularly humans.
Owner:MERCK SHARP & DOHME CORP

Use of a viscoelastic composition for treating increased intraocular pressure

A viscoelastic medium is useful for the manufacture of a medicament, such as a medical device, for treatment of increased intraocular pressure in the eye of a human or animal. The medicament is administerable into at least one sclerally penetrating fistula of the eye such that the fistula is filled with the medicament. The medium is also useful in a method of treating increased intraocular pressure in the eye of a human or an animal in need thereof, comprising the step of injecting the viscoelastic medium into at least one sclerally penetrating fistula in the eye such that the fistula is filled with the medium.
Owner:Q MED AB

Implanted retina support

The invention provides an implanted retina support. The support is of a hollowed-out spherical supporting structure which is matched with the entocoele of the eyeball, looks transparent, and can be elastically deformed. The implanted retina support has the following advantages that hollowed-out design of the retina support can avoid increasing of intraocular pressure caused by aqueous fluid circulation obstacles, and reduce the occurrence of postoperative complications.
Owner:SHANGHAI TONGJI HOSPITAL

Methods for treating glaucoma and macular degeneration

Inhibition of geranylgeranylation of Rho GTPases and heterotrimeric G-proteins in the aqueous outflow pathway increases aqueous humor outflow, possibly through the tissue relaxation, and through altered cell adhesive interactions and actin cytoskeletal organization in cells of the outflow pathway. In addition, such inhibition is useful for treating age-related macular degeneration. The GGTase-I enzyme is a molecular target for lowering increased ocular pressure in glaucoma patients.
Owner:PHARMACO INVESTMENTS

Optic nerve repair composition as well as preparation method and application thereof

The invention relates to an optic nerve repair composition as well as a preparation method and application thereof. The preparation method comprises the following steps of mixing an Rho kinase inhibitor, activated platelet-rich plasma and stem cells, and performing culture at 2-37 DEG C for 8-72 hours to obtain the optic nerve repair composition. Specifically for pathogenic factors of vascular dysfunction, intraocular pressure rise and optic nerve cell injury of ophthalmic disease patients, the stem cells, the PRP and the Rho kinase inhibitor are combined for the first time, and a set of new three-dimensional cascade interaction mechanism is established. The tight synergistic effect of the PRP, the stem cells and the Rho kinase inhibitor prompts that the PRP and the Rho kinase inhibitor can jointly secrete cytokines, promote vascular endothelium and optic nerve cell repair, reconstruct vascular functions, reduce intraocular pressure, reduce retinal damage and reduce retinal cell apoptosis by promoting the function of EPC.
Owner:GUANGZHOU ZHUNYOU BIOLOGICAL TECH CO LTD +1

Combinations of prostaglandins and nitric oxide donors

The present invention relates to compositions for treating glaucoma and elevated ocular pressure. The compositions comprise a nitric oxide releasing isomannide derivative and a prostaglandin F2[alpha] analog.
Owner:NICOX SA

Application of lauromacrogol in preparation of chronic intraocular hypertension animal model and animal model

The invention discloses application of lauromacrogol in preparation of a chronic intraocular hypertension animal model. The chronic intraocular hypertension animal model can be constructed by injecting lauromacrogol into suprascleral veins of a model animal, especially an animal model with chronic mild intraocular pressure rise. The model construction method is simple, the intraocular hypertension maintaining time is long, and complications do not exist. The chronic intraocular hypertension animal model can be used for simulating the chronic intraocular pressure rising process of open-angle glaucoma of people, is suitable for animal experiment research of screening glaucoma treatment drugs and glaucoma pathogenesis research, and has the application value of preclinical research.
Owner:CENT SOUTH UNIV

Glaucoma aqueous humor drainage device and glaucoma aqueous humor drainage method

A glaucoma aqueous humor drainage device and a glaucoma aqueous humor drainage method, wherein the opening and closing of a pressure valve is controlled by the change in the pressure in a cavity of the valve. When the pressure in the intraocular pressure exceeds 12 mmHg, the valve is opened, and a drainage tube connected behind the valve drains the aqueous humor to the ocular surface, reducing the patient's discomfort and dry eyes, effectively draining the aqueous humor and avoiding scarring caused by embedding the device via a conjunctival flap and operation failure caused by increase of intraocular pressure caused by generation of filtering blebs.
Owner:THE EYE HOSPITAL OF WENZHOU MEDICAL UNIV

Application of JTE-013 in preparation of medicine for protecting glaucoma optic nerve injury

The invention discloses an application of JTE-013 in preparation of a medicine for protecting glaucoma optic nerve injury. According to the application, the JTE-013 is applied to treatment of an ischemia reperfusion model of a glaucoma related animal model for the first time, the treatment effect of the JTE-013 is determined, and the JTE-013 can obviously improve retinal ganglion cell injury caused by increase of intraocular pressure; axonal injury caused by increase of intraocular pressure can be obviously improved; the activation of microglial cells can be obviously inhibited; myelin sheath regeneration and proliferation of myelin sheath formation cell oligodendroglia cells can be obviously promoted; the visual function can be obviously recovered.
Owner:ZHONGSHAN OPHTHALMIC CENT SUN YAT SEN UNIV

Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound

The object of the present invention is to find a new application of isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof. Isopropyl (6-{ [4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminometh yl}pyridin-2-ylamino) acetate or a salt thereof is useful as a therapeutic agent for a disease involving a greatly elevated intraocular pressure.
Owner:SANTEN PHARMA CO LTD

Gel and preparation method thereof

The invention discloses gel and a preparation method thereof, and belongs to the field of tissue material engineering. The gel is prepared from active substances comprising the following three components, wherein the first component is PEG (Polyethylene Glycol) modified by N-hydroxysuccinimide-glutaric acid ester; the second component is polylysine; and the third component is a thickening agent. The active substance does not include amino-modified polyethylene glycol and amino-modified polyoxyethylene derivatives. The swelling property of the gel disclosed by the invention can keep low swelling and low shrinkage in a range of up to 180 days, which is a key factor for ophthalmology use because if the swelling rate of the vitreous body substitute is high, intraocular pressure can be increased to cause glaucoma, and if the swelling rate of the fundus gel is high, the retina can be pulled to cause retinal detachment.
Owner:JIANGSU DISSUETECH MEDICAL TECH CO LTD

Application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy

The invention discloses application of ceritinib in preparation of medicine for treating thyroid-associated ophthalmopathy, and relates to the field of medicines. The pathogenesis of thyroid-related ophthalmopathy is complex, and clinical phenotypes such as eyeball protrusion and intraocular pressure increase are finally caused by adipose precursor cell differentiation enhancement in eye sockets, large-amount secretion of inflammatory factors and the like. According to the invention, lipid accumulation condition of cells subjected to complete fat induced differentiation is evaluated by virtue of Bodipy dyeing and high-content instrument analysis so as to screen drugs capable of effectively inhibiting fat differentiation and lipid accumulation. The result shows that ceritinib has an obvious inhibiting effect on fat differentiation of human orbital fibroblasts, and can inhibit expression of inflammatory factors induced by IL-17A. Thus, the treatment effect of ceritinib on thyroid-related eye diseases is verified.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

Compound neomycin sulfate eye drops as well as preparation method and application thereof

The invention relates to compound neomycin sulfate eye drops as well as a preparation method and application thereof, and belongs to the technical field of eye drops for pets. The compound neomycin sulfate eye drops comprise the following components in percentage by weight: 0.1%-1% of neomycin sulfate, 0.1%-1% of acetazolamide, 0%-2% of dipotassium glycyrrhizinate and 0.5%-1.5% of sodium hyaluronate. Acetazolamide is used for replacing dexamethasone in traditional compound neomycin sulfate eye drops, adverse reactions caused by long-term use of neomycin sulfate can be avoided, the technical problem that dexamethasone easily causes ocular pressure rise of pets is solved, and the compound neomycin sulfate eye drops are milder and non-irritant to the eyes; and compared with the prior art, thecompound neomycin sulfate eye drops have the advantages that not only can symptoms such as conjunctival congestion, redness and swelling and secretion increase caused by conjunctivitis of pets be effectively solved, but also side effects such as eye itch, couperose skin and eye dryness of the pets caused by inappropriate eye drops can be reduced.
Owner:合肥中龙神力动物药业有限公司

Effect of ws6 on actin formation in trabecular meshwork cells

The invention discloses influence of WS6 on actin formation of trabecular meshwork cells. WS6 refers to anti-diabetic medicine glibenclamide, sodium orthovanadate and an active compound capable of promoting pancreatic beta cell proliferation. WS6 has cytotoxicity on the trabecular meshwork cells and inhibits actin formation of the trabecular meshwork cells. The influence of WS6 has the beneficialeffect that the fact that WS6 can remarkably inhibit actin formation, caused by TRPV4 agonist GSK101, of the trabecular meshwork cells is revealed. Intraocular pressure can be reduced, and the influence of WS6 has potential treatment significance in glaucoma caused by increase of intraocular pressure.
Owner:QINGDAO UNIV

Silicone Oil-Induced Ocular Hypertension Glaucoma Model

Injection of silicon oil (SO) to the anterior chamber of an eye efficiently induces intraocular pressure (IOP) elevation. This effect occurs without causing overt ocular structural damage or inflammatory responses while simulating acute glaucomatous changes that human patients develop over years by inducing progressive RGC and ON degeneration and visual functional deficits within weeks. The anterior segments of the experimental eyes are not substantially affected, leaving clear ocular elements that allow easy and reliable assessment of in vivo visual function and morphology. More importantly, this is the only reversible ocular hypertension model by removing SO from the anterior chamber and particularly useful for testing neuro-protection treatment together with lowering IOP treatment. In summary, the acute ocular hypertension glaucoma model replicates secondary post-operative glaucoma. It is straightforward and reversible, does not require special equipment or repeat injections, and may be applicable to a range of animal species with only minor modifications.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Self-centering phakic refractive lenses with parachute design

An improved self-centering phakic refractive lens is disclosed. The lens floats freely in the posterior chamber of the eye and corrects vision of the patient but also prevents buildup of intraocular pressure, cataract induction and iris pigment dispersion. The lens comprises an optical body, haptic members which extend outward from the optical body, and a small hole in the approximate center of the optical body for the purpose of allowing aqueous humor to flow through that hole. The lens is designed such that its posterior surface conforms to the shape of the anterior surface of the patient's natural crystalline lens.
Owner:MEDENNIUM

Glaucoma aqueous humor drainage device and glaucoma aqueous humor drainage method

A glaucoma aqueous humor drainage device and a glaucoma aqueous humor drainage method, wherein the opening and closing of a pressure valve is controlled by the change in the pressure in a cavity of the valve. When the pressure in the intraocular pressure exceeds 12 mmHg, the valve is opened, and a drainage tube connected behind the valve drains the aqueous humor to the ocular surface, reducing the patient's discomfort and dry eyes, effectively draining the aqueous humor and avoiding scarring caused by embedding the device via a conjunctival flap and operation failure caused by increase of intraocular pressure caused by generation of filtering blebs.
Owner:THE EYE HOSPITAL OF WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products